Abstract
BackgroundTofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA).ObjectivesTo describe the safety profile of tofacitinib from integrated Phase (P)3 and long-term extension (LTE) studies.MethodsData were analysed...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
